1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
A Phase 1 Study of Anti-CD64 CAR T Cells in Patients with Venetoclax-refractory Myeloid Neoplasms is sponsored by Blood Cancer United (formerly The Leukemia & Lymphoma Society). This grant supports a phase 1 clinical trial of a novel CAR T cell therapy developed at the University of Colorado Anschutz, targeting a specific protein (CD64) found on leukemia cells resistant to standard therapies in patients with treatment-resistant acute myeloid leukemia (AML).
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Academic institutions and researchers focused on clinical trials for novel CAR T-cell therapies in blood cancers. Specifically, the Gates Institute at the University of Colorado Anschutz received this award. Confirm the full requirements in the official notice before applying.
A Phase 1 Study of Anti-CD64 CAR T Cells in Patients with Venetoclax-refractory Myeloid Neoplasms is funded by Blood Cancer United (formerly The Leukemia & Lymphoma Society). Verify program details on the funder's official page before applying.
This opportunity targets applicants in Colorado. If your organization operates elsewhere, check the official notice for location requirements.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
The $46M FSHARP program is creating shelf-stable synthetic blood from freeze-dried components. A new SWiFT SBIR topic opened May 6 for autonomous field transfusion devices. What grant seekers in biomedical engineering need to know.
Read articleThe Breast Cancer Research Foundation launched a $100 million venture philanthropy fund at CGI on September 22, 2026, seeded with $23 million and aiming at 20 to 30 companies. Here is what the structure actually means for investigators, for startups in the valley of death, and for every disease foundation now weighing the same move.
Read articleCDC-RFA-DP-27-0023 puts the National Breast and Cervical Cancer Early Detection Program, the National Comprehensive Cancer Control Program, and the National Program of Cancer Registries into a single competition closing February 5, 2027. Three statutorily separate eligibility pools, one application deadline, and an award count that maps onto the incumbent footprint. Here is how to read that.
Read article